MaxCyte, Inc. (MXCT)Healthcare | Medical Devices | Rockville, United States | NasdaqGS
1.22 USD
-0.06
(-4.688%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.21 -0.01 (-0.008%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:55 a.m. EDT
The investment case for MaxCyte is currently fractured by a severe disconnect between optimistic analyst sentiment and deteriorating reality. While analysts maintain a 'strong buy' rating with a $4.10 target, the company's fundamentals tell a starkly different story: revenue has contracted by 14.5%, operating cash flow is negative, and the stock has erased over 90% of its value over the last four years. The recent price action shows a fragile recovery from August lows, but this bounce lacks the volume and breadth to confirm a trend reversal. The options market confirms this skepticism, with traders stacking puts at the $0.50 level to catch further declines rather than betting on a rally. Until the company demonstrates a path to profitability and stabilizes its top-line growth, the risk-reward profile remains skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.069951 |
| MSTL | 0.071476 |
| AutoTheta | 0.267979 |
| AutoARIMA | 0.330819 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.779 |
| Excess Kurtosis | -0.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.867 |
| Revenue per Share | 0.291 |
| Market Cap | 125,911,576 |
| Forward P/E | -4.97 |
| Beta | 1.49 |
| Profit Margins | -114.77% |
| Website | https://www.maxcyte.com |
As of Aug. 22, 2026, 2:55 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest is heavily concentrated at the $0.50 strike, acting as a significant floor, while call activity is sparse and focused on deep out-of-the-money strikes ($5.00) suggesting speculative lottery tickets rather than directional bets. The lack of volume in near-term calls indicates a lack of immediate bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08955222 |
| Address1 | 9,713 Key West Avenue |
| Address2 | Suite 400 |
| All Time High | 17.44 |
| All Time Low | 0.643 |
| Ask | 1.57 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 528,850 |
| Average Daily Volume3 Month | 1,104,288 |
| Average Volume | 1,104,288 |
| Average Volume10Days | 528,850 |
| Beta | 1.494 |
| Bid | 1.22 |
| Bid Size | 4 |
| Board Risk | 6 |
| Book Value | 1.496 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.22 |
| Current Ratio | 12.256 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.3 |
| Day Low | 1.21 |
| Debt To Equity | 10.867 |
| Display Name | MaxCyte |
| Earnings Call Timestamp End | 1,786,566,600 |
| Earnings Call Timestamp Start | 1,786,566,600 |
| Earnings Timestamp | 1,786,564,800 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -30,288,000 |
| Ebitda Margins | -0.97543 |
| Enterprise To Ebitda | -1.237 |
| Enterprise To Revenue | 1.207 |
| Enterprise Value | 37,472,572 |
| Eps Current Year | -0.27801 |
| Eps Forward | -0.24528 |
| Eps Trailing Twelve Months | -0.33 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2324 |
| Fifty Day Average Change | -0.012399912 |
| Fifty Day Average Change Percent | -0.010061597 |
| Fifty Two Week Change Percent | -8.955222 |
| Fifty Two Week High | 1.865 |
| Fifty Two Week High Change | -0.645 |
| Fifty Two Week High Change Percent | -0.34584448 |
| Fifty Two Week Low | 0.643 |
| Fifty Two Week Low Change | 0.577 |
| Fifty Two Week Low Change Percent | 0.89735615 |
| Fifty Two Week Range | 0.643 - 1.865 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 93,716,395 |
| Forward Eps | -0.24528 |
| Forward P E | -4.9739075 |
| Free Cashflow | -13,138,125 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 91 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -4.6875 |
| Fullday Price | 1.2125 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.79227996 |
| Gross Profits | 24,601,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01653 |
| Held Percent Institutions | 0.62048 |
| Implied Shares Outstanding | 103,206,206 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. |
| Long Name | MaxCyte, Inc. |
| Market | us_market |
| Market Cap | 125,911,576 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_4048262 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -35,636,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 132,103,943 |
| Number Of Analyst Opinions | 4 |
| Open | 1.3 |
| Operating Cashflow | -22,977,000 |
| Operating Margins | -1.40723 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 301 944 1700 |
| Post Market Change | -0.0075000525 |
| Post Market Change Percent | -0.6147584 |
| Post Market Price | 1.2125 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 1.28 |
| Price Eps Current Year | -4.3883314 |
| Price Hint | 4 |
| Price To Book | 0.815508 |
| Price To Sales Trailing12 Months | 4.0549927 |
| Profit Margins | -1.14766 |
| Quick Ratio | 11.078 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -4.6875 |
| Regular Market Day High | 1.3 |
| Regular Market Day Low | 1.21 |
| Regular Market Day Range | 1.21 - 1.3 |
| Regular Market Open | 1.3 |
| Regular Market Previous Close | 1.28 |
| Regular Market Price | 1.22 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 563,088 |
| Return On Assets | -0.10641 |
| Return On Equity | -0.20393999 |
| Revenue Growth | -0.145 |
| Revenue Per Share | 0.291 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,206,206 |
| Shares Percent Shares Out | 0.0119 |
| Shares Short | 1,225,669 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,406,444 |
| Short Name | MaxCyte, Inc. |
| Short Percent Of Float | 0.012 |
| Short Ratio | 1.27 |
| Source Interval | 15 |
| State | MD |
| Symbol | MXCT |
| Target High Price | 5.0 |
| Target Low Price | 2.43 |
| Target Mean Price | 4.1075 |
| Target Median Price | 4.5 |
| Total Cash | 105,690,000 |
| Total Cash Per Share | 1.024 |
| Total Debt | 17,251,000 |
| Total Revenue | 31,051,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.130635 |
| Two Hundred Day Average Change | 0.089365005 |
| Two Hundred Day Average Change Percent | 0.079039656 |
| Type Disp | Equity |
| Volume | 563,088 |
| Website | https://www.maxcyte.com |
| Zip | 20,850 |